Emergent BioSolutions Inc. (EBS) Revenue by Segment & Business Profile
Medical Countermeasures MCM Product was 71.7% of Emergent BioSolutions Inc.'s revenue across the 3 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 319.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
What the company does
Emergent BioSolutions Inc. is a drug manufacturers - specialty & generic company in the healthcare sector. In its SEC filings it reports 3 business lines: Medical Countermeasures MCM Product (72%), Commercial Product (22%), Other (6%). Trailing twelve-month revenue: $770.2 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Specialty pharma
Revenue by geography
fiscal year 2025 · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 531M | 71.5% | -35.4% |
| Other Geographical Area | 137M | 18.4% | +69.7% |
| Canada | 75M | 10.1% | -46.6% |
Emergent BioSolutions Inc. — questions
- What does Emergent BioSolutions Inc. do?
- Emergent BioSolutions Inc. is a drug manufacturers - specialty & generic company in the healthcare sector. In its SEC filings it reports 3 business lines: Medical Countermeasures MCM Product (72%), Commercial Product (22%), Other (6%). Trailing twelve-month revenue: $770.2 million as of 2026-06-30.
- How does Emergent BioSolutions Inc. make money?
- By the lines it reports in its SEC filings: Medical Countermeasures MCM Product 71.7%, Commercial Product 22.4%, Other 5.9% of revenue.
Every figure on this page comes from Emergent BioSolutions Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.